Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Hematologic Malignancies
•
Medical Oncology
•
Myelodysplastic Syndromes
•
Hematology
Would you continue long-term treatment with hypomethylating agents for patients with MDS who have no hematologic response, in order to decrease risk of future leukemic progression?
Related Questions
What is your approach for choosing between Imetelstat and Luspatercept in managing MDS related anemia?
How do you approach severe anemia and thrombocytopenia in an elderly patient whose bone marrow biopsy shows hypercellular marrow with mild dysplasia in erythroid and megakaryocytic lineage but normal cytogenetics and a negative NGS panel?
Would you hold off iron chelation in a transfusion dependent MDS patient with elevated ferritin but with negative iron stain on the bone marrow?
How do you manage a patient with low risk MDS who achieves transfusion independence with luspatercept but continues to have fatigue?
How do you approach management for CCUS with severe cytopenias?
Do you add venetoclax +/- anti CD-20 mAb to a BTKi in patients with CLL who no longer wish to remain on a BTKi many months after starting the BTKi?
What is your approach to treatment of relapsed, high-risk MDS with TP53 mutation in a patient that is not considered a transplant candidate?
Is there a role for CRS prophylaxis with tocilizumab during bispecific T cell engager initiation for myeloma?
When, if ever, would you select a three-drug regimen instead of four-drug regimen in patients with newly diagnosed Multiple Myeloma?
For essential thrombocythemia with an indication for aspirin, would you defer therapy if they are on celecoxib?
